Platelet [3H]-imipramine binding is not modified in Alzheimer's disease.
Platelet [3H]-imipramine binding was studied in patients with Alzheimer's disease and control subjects matched to the patients for age and sex. There were no differences in the binding parameters of [3H]-imipramine on platelet membranes from patients with Alzheimer's disease, when compared with the control group. These results suggest that [3H]-imipramine binding could be a useful tool to discriminate between demented and depressive patients in elderly populations.
Galzin
A M
AM
Laboratoires d'Etudes et de Recherches Synthélabo (L.E.R.S.), Paris, France.
Davous
P
P
Roudier
M
M
Lamour
Y
Y
Poirier
M F
MF
Langer
S Z
SZ
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood*; D001792:Blood Platelets / Q000378:metabolism*; D002352:Carrier Proteins; D003866:Depressive Disorder / Q000097:blood; D005260:Female; D006801:Humans; D007099:Imipramine / Q000493:pharmacokinetics*; D008297:Male; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter / Q000378:metabolism*
D002352:Carrier Proteins; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter; C027775:imipramine receptor; D007099:Imipramine